Holen Sie sich die Stockscreener-App
29.32
1.74%
-0.5122
Schlusskurs vom Vortag:
$29.83
Offen:
$29.93
24-Stunden-Volumen:
117.33K
Relative Volume:
0.23
Marktkapitalisierung:
$1.36B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-166.31M
KGV:
-6.5732
EPS:
-4.4602
Netto-Cashflow:
$-160.59M
1W Leistung:
-2.46%
1M Leistung:
+17.39%
6M Leistung:
+59.39%
1J Leistung:
+48.86%
1-Tages-Spanne:
$29.14
$30.41
1-Wochen-Bereich:
$28.99
$31.87
52-Wochen-Spanne:
$16.10
$32.14
Arrivent Biopharma Inc Stock (AVBP) Company Profile
Firmenname
Arrivent Biopharma Inc
Sektor
Branche
Telefon
240-780-6356
Adresse
18 CAMPUS BLVD., NEWTOWN SQUARE
Compare AVBP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVBP
Arrivent Biopharma Inc
|
29.30 | 1.38B | 0 | -166.31M | -160.59M | -4.4602 |
VRTX
Vertex Pharmaceuticals Inc
|
425.05 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
717.53 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
805.51 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.06 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
314.37 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arrivent Biopharma Inc Stock (AVBP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-12 | Fortgesetzt | BTIG Research | Buy |
| 2025-12-10 | Eingeleitet | BTIG Research | Buy |
| 2025-11-25 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Buy |
| 2025-03-20 | Eingeleitet | B. Riley Securities | Buy |
| 2025-03-10 | Eingeleitet | Guggenheim | Buy |
| 2024-07-22 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-02-20 | Eingeleitet | Citigroup | Buy |
| 2024-02-20 | Eingeleitet | Goldman | Buy |
| 2024-02-20 | Eingeleitet | Jefferies | Buy |
Alle ansehen
Arrivent Biopharma Inc Aktie (AVBP) Neueste Nachrichten
FY2026 Earnings Estimate for AVBP Issued By Lifesci Capital - MarketBeat
ArriVent BioPharma: A First Assessment (NASDAQ:AVBP) - Seeking Alpha
[ARS] ArriVent BioPharma, Inc. SEC Filing - Stock Titan
ArriVent BioPharma (NASDAQ: AVBP) details 2026 virtual meeting, board elections and CEO pay - Stock Titan
Buy Rating Reaffirmed on ArriVent as Firmonertinib Data Boost Confidence; $42 Price Target Maintained - TipRanks
Why (AVBP) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Are you looking for a top momentum pick? Why ArriVent BioPharma, Inc. (AVBP) is a great choice - MSN
Citigroup Increases ArriVent BioPharma (NASDAQ:AVBP) Price Target to $45.00 - MarketBeat
Citi Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Raises Target Price to $45 - Moomoo
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Cantor Fitzgerald initiates coverage of ArriVent BioPharma (AVBP) with overweight recommendation - MSN
Are medical stocks lagging ArriVent BioPharma, Inc. (AVBP) this year? - MSN
ArriVent BioPharma (NASDAQ:AVBP) Hits New 12-Month HighWhat's Next? - MarketBeat
Vicor, AXT And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Stocks generating improved relative strength: ArriVent BioPharma - MSN
What macro factors move ArriVent (AVBP) stock most (Stalls) 2026-04-18Community Risk Signals - Xã Vĩnh Công
Arrivent Biopharma stock hits 52-week high at $29.56 By Investing.com - Investing.com Australia
ArriVent BioPharma, Inc. (AVBP) Stock Analysis: Exploring a 38.82% Upside Potential in the Biotech Sector - DirectorsTalk Interviews
Arrivent Biopharma stock hits 52-week high at $29.56 - Investing.com
Are medical stocks lagging AstraZeneca (AZN) this year? - MSN
ArriVent BioPharma (NASDAQ:AVBP) Hits New 1-Year HighTime to Buy? - MarketBeat
Wall Street analysts think ArriVent BioPharma, Inc. (AVBP) could surge 72.44%: Read this before placing a bet - MSN
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice - Yahoo Finance
Understanding Momentum Shifts in (AVBP) - Stock Traders Daily
Are Medical Stocks Lagging AstraZeneca (AZN) This Year? - Yahoo Finance
Guggenheim Maintains ArriVent BioPharma(AVBP.US) With Buy Rating, Maintains Target Price $45 - Moomoo
ArriVent BioPharma (NASDAQ:AVBP) Sets New 12-Month HighShould You Buy? - MarketBeat
Surprises Report: How does SAPH compare to its peers2026 Macro Impact & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Arrivent Biopharma stock hits 52-week high at 27.25 USD By Investing.com - Investing.com Australia
Arrivent Biopharma stock hits 52-week high at 27.25 USD - Investing.com
Is ArriVent (AVBP) Stock Risky Now | Price at $25.23, Up 0.16%Turnaround Stocks - Newser
ArriVent BioPharma, Inc. (AVBP) Stock Price, News, Quote & History - Yahoo! Finance Canada
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet - Yahoo Finance
Is ArriVent (AVBP) Stock Declining | Price at $25.23, Up 1.37%Global Trading Community - Newser
Wall Street experts predict that ArriVent BioPharma, Inc. (AVBP) may climb by 72.44%. Check this out before making any investment decisions. - bitget.com
ArriVent to present preclinical cancer drug data at AACR 2026 - MSN
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest - Yahoo Finance
AVBP Technical Analysis & Stock Price Forecast - Intellectia AI
Avoiding Lag: Real-Time Signals in (AVBP) Movement - Stock Traders Daily
AVBP Q4 2025 Earnings: ArriVent BioPharma Inc. tops EPS views, no revenue - Cổng thông tin điện tử Tỉnh Sơn La
Clear Street Initiates Coverage of ArriVent BioPharma (AVBP) with Buy Recommendation - MSN
Gains Report: Whats next for ArriVent BioPharma Inc stock2026 Technicals & Weekly Breakout Stock Alerts - baoquankhu1.vn
Aug Highlights: How do insiders feel about ArriVent BioPharma IncAnalyst Upgrade & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
ArriVent BioPharma (NASDAQ:AVBP) Trading Up 8.4%Here's Why - MarketBeat
Aug Mood: Can ArriVent BioPharma Inc maintain sales growth2026 Investor Takeaways & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum Shift - Sahm
Finanzdaten der Arrivent Biopharma Inc-Aktie (AVBP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Arrivent Biopharma Inc-Aktie (AVBP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LaChapelle Robin | Chief Operating Officer |
Jul 11 '25 |
Option Exercise |
2.28 |
11,153 |
25,429 |
135,736 |
0.78%
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):